Minda Industries issues commercial papers worth Rs 50 crore; climbs over 3 per cent
Minda Industries issues commercial papers worth Rs 50 crore; climbs over 3 per cent

Minda Industries issues commercial papers worth Rs 50 crore; climbs over 3 per cent

Ganesh V Article rating: 3.0

Minda Industries announced on Friday that it has issued commercial papers of Rs 50 crore with an allotment date of March 18, 2021, which is due to mature on June 16, 2021. The company has issued these commercial papers to bring down the finance cost. 

Weekly Economic Update
Weekly Economic Update

Weekly Economic Update

Srinivasa Sharan Article rating: 3.5

A sumary of the most important economic news for the week including the US central bank's decision on interest rates

Sensex, Nifty close in green; Intellect Design jumps 14 per cent, Aarti Drugs gains 10 per cent, Future Group stocks plunge
Sensex, Nifty close in green; Intellect Design jumps 14 per cent, Aarti Drugs gains 10 per cent, Future Group stocks plunge

Sensex, Nifty close in green; Intellect Design jumps 14 per cent, Aarti Drugs gains 10 per cent, Future Group stocks plunge

Geyatee Deshpande Article rating: 5.0

Bulls made a comeback at D-Street as domestic benchmark indices snapped their 5-day losing streak to end the week in the positive territory. On Friday, Sensex surged by 641.72 points or by 1.30 per cent, to close at 49,858.24 levels while Nifty jumped by 186.15 points or 1.28 per cent to settle at 14,744 levels. 

Stelis Biopharma winds up series B & C fundraise amounting to US$ 195 million
Stelis Biopharma winds up series B & C fundraise amounting to US$ 195 million

Stelis Biopharma winds up series B & C fundraise amounting to US$ 195 million

Shruti Dahiwal Article rating: 5.0

Stelis Biopharma, a pharmaceutical division of Strides Pharma Science Ltd, announced today that it has successfully completed its series B & C fundraise which amounted to US$ 195 million. This fundraise reinforces the growth potential of the company and enables the company to pursue growth initiatives and scale-up its business further.

RSS
First24092410241124122414241624172418Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR